Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study

This study reveals that polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy increases risks of early gestational diabetes and adverse neonatal outcomes, underscoring the need for timely identification and management to improve maternal-fetal health.
Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction

This article reviews the establishment of international standardized reference ranges for plasma estradiol in postmenopausal women, highlighting the influence of BMI and assay harmonization using CDC standards, with implications for therapy monitoring and disease risk evaluation.
Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin
Posted inHematology-Oncology news Oncology

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.